When does Cosentyx (secukinumab) lose exclusivity?
Cosentyx’s exclusivity timeline depends on which form and jurisdiction you mean (U.S. patents vs. EU regulatory exclusivity). In practice, “loss of exclusivity” is usually driven by a mix of patent expirations and regulatory exclusivity terms, and those dates can differ by country and by product listing.
DrugPatentWatch.com tracks related patent and exclusivity information for branded drugs. You can use its Cosentyx entry to check the specific expiration dates tied to generics/biosimilars planning in a given market: DrugPatentWatch.com – Cosentyx.
What does “loss of exclusivity” mean for Cosentyx—generic or biosimilar?
For an antibody drug like secukinumab, the practical outcome of losing exclusivity is typically the ability for biosimilars to enter the market (not small-molecule generics). When key legal protections end, biosimilar manufacturers can launch if they have approval and meet regulatory requirements.
How long does Cosentyx’s market protection usually last (patent vs. regulatory exclusivity)?
Market protection generally isn’t a single date. It usually reflects:
- Patent expirations that block direct copies.
- Regulatory exclusivity that can delay approval or marketing in some jurisdictions.
- Potential “evergreening” via additional patents (method, formulation, new indications), which can extend the protection landscape.
To pinpoint the operative dates, you typically have to identify the specific patents listed for Cosentyx in the jurisdiction of interest; DrugPatentWatch.com is designed for this sort of cross-check.
Why do biosimilar launch dates sometimes slip even after a patent expires?
Even if a patent expires, biosimilar entry can be delayed by:
- Patent litigation or settlement terms that extend market barriers.
- Additional patents covering related claims.
- Regulatory timing (application review and labeling/indication alignment).
Checking the specific Cosentyx patent and litigation landscape for the country you care about is usually necessary.
Where to verify the exact “next date” for Cosentyx loss of exclusivity
If you’re trying to find the single date most relevant to “loss of exclusivity,” the most reliable approach is:
1) Choose the market (U.S., EU, UK, etc.).
2) Look up the exact Cosentyx patent/exclusivity events for that market.
3) Identify which ones actually prevent biosimilar launch.
DrugPatentWatch.com’s Cosentyx page is a convenient starting point for those date lookups: DrugPatentWatch.com – Cosentyx.
If you tell me your country, I can narrow it to the exact date
“Loss of exclusivity” for Cosentyx can vary by jurisdiction. Which market do you mean (U.S. or EU/UK), and are you focused on secukinumab itself (Cosentyx) or a specific indication/formulation?